Strength Seen in Schrodinger (SDGR): Can Its 13.8% Jump Turn into More Strength?

Schrodinger, Inc. SDGR shares soared 13.8% in the last trading session to close at $21.98. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.7% loss over the past four weeks.Schrodinger scored a strong price increase, driven by the optimism surrounding its upcoming third-quarter 2025 financial results, expected to release next month. In the last reported quarter, higher software and drug discovery revenue drove a 16% year-over-year growth in the company’s top-line.This company is expected to post quarterly loss of $0.72 per share in its upcoming report, which represents a year-over-year change of -38.5%. Revenues are expected to be $52.68 million, up 49.3% from the year-ago quarter.While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For Schrodinger, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SDGR going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Schrodinger is part of the Zacks Medical Info Systems industry. Fulgent Genetics, Inc. FLGT, another stock in the same industry, closed the last trading session 5.1% higher at $23.84. FLGT has returned 1.6% in the past month.Fulgent Genetics' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.24. Compared to the company's year-ago EPS, this represents a change of -177.4%. Fulgent Genetics currently boasts a Zacks Rank of #3 (Hold).5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They includeStock #1: A Disruptive Force with Notable Growth and ResilienceStock #2: Bullish Signs Signaling to Buy the DipStock #3: One of the Most Compelling Investments in the MarketStock #4: Leader In a Red-Hot Industry Poised for GrowthStock #5: Modern Omni-Channel Platform Coiled to SpringMost of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Schrodinger, Inc. (SDGR): Free Stock Analysis Report Fulgent Genetics, Inc. (FLGT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks